Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Hanmi’s Once Weekly Efpeglenatide Bests Liraglutide In Phase II

This article was originally published in PharmAsia News

Executive Summary

In its ongoing push to seek a global partner for its diabetes therapies, South Korea's major pharma firm Hanmi has presented the results of Phase IIb study for a once weekly form of its diabetes therapy efpeglenatide, which showed benefits over Novo Nordisk’s rival therapy Victoza.


Related Content

Novo Nordisk Plans Q1 Launch Of Long-Acting Insulin Tresiba


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst